TrialScandinavian journal of rheumatology2016

Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.

K-H Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.